Transcriptome Analysis Reveals Anti-Cancer Effects of Isorhapontigenin (ISO) on Highly Invasive Human T24 Bladder...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Muscle invasive bladder cancer (MIBC) has a poor prognosis, necessitating novel therapeutic strategies.
• Isorhapontigenin (ISO), a stilbene derivative, demonstrates significant anti-cancer activity against MIBC.
• Identifying molecular targets of ISO is crucial for developing effective bladder cancer treatments.

Purpose of the Study:

• To investigate the molecular effects of Isorhapontigenin (ISO) on human bladder cancer T24 cells using whole transcriptome profiling.
• To identify differentially expressed genes (DEGs) and associated pathways affected by ISO treatment.
• To elucidate the mechanisms by which ISO influences cancer cell behavior and the tumor microenvironment.

Main Methods:

• Whole transcriptome sequencing was performed on human bladder cancer T24 cells treated with ISO.
• Differential gene expression analysis was conducted to identify upregulated and downregulated genes.
• Functional annotation and pathway analysis were used to interpret the biological significance of gene expression changes.

Main Results:

• A total of 1047 differentially expressed genes (DEGs) were identified, with 596 downregulated and 451 upregulated.
• ISO treatment significantly altered gene expression related to cell movement, migration, invasion, metabolism, proliferation, and angiogenesis.
• Key pathways affected include inflammation (activated), hypoxia signaling, glycolysis, actin cytoskeleton, and tumor microenvironment (repressed).

Conclusions:

• ISO treatment induces substantial changes in gene expression in bladder cancer cells, affecting critical cellular processes.
• The observed metabolic shift and altered actin cytoskeleton in ISO-treated cells contribute to tumor microenvironment remodeling.
• These molecular alterations suggest that ISO has the potential to suppress tumor growth and progression in MIBC.